Hosseini, I.; Fleisher, B.; Getz, J.; Decalf, J.; Kwong, M.; Ovacik, M.; Bainbridge, T.W.; Moussion, C.; Rao, G.K.; Gadkar, K.;
et al. A Minimal PBPK/PD Model with Expansion-Enhanced Target-Mediated Drug Disposition to Support a First-in-Human Clinical Study Design for a FLT3L-Fc Molecule. Pharmaceutics 2024, 16, 660.
https://doi.org/10.3390/pharmaceutics16050660
AMA Style
Hosseini I, Fleisher B, Getz J, Decalf J, Kwong M, Ovacik M, Bainbridge TW, Moussion C, Rao GK, Gadkar K,
et al. A Minimal PBPK/PD Model with Expansion-Enhanced Target-Mediated Drug Disposition to Support a First-in-Human Clinical Study Design for a FLT3L-Fc Molecule. Pharmaceutics. 2024; 16(5):660.
https://doi.org/10.3390/pharmaceutics16050660
Chicago/Turabian Style
Hosseini, Iraj, Brett Fleisher, Jennifer Getz, Jérémie Decalf, Mandy Kwong, Meric Ovacik, Travis W. Bainbridge, Christine Moussion, Gautham K. Rao, Kapil Gadkar,
and et al. 2024. "A Minimal PBPK/PD Model with Expansion-Enhanced Target-Mediated Drug Disposition to Support a First-in-Human Clinical Study Design for a FLT3L-Fc Molecule" Pharmaceutics 16, no. 5: 660.
https://doi.org/10.3390/pharmaceutics16050660
APA Style
Hosseini, I., Fleisher, B., Getz, J., Decalf, J., Kwong, M., Ovacik, M., Bainbridge, T. W., Moussion, C., Rao, G. K., Gadkar, K., Kamath, A. V., & Ramanujan, S.
(2024). A Minimal PBPK/PD Model with Expansion-Enhanced Target-Mediated Drug Disposition to Support a First-in-Human Clinical Study Design for a FLT3L-Fc Molecule. Pharmaceutics, 16(5), 660.
https://doi.org/10.3390/pharmaceutics16050660
